Kangchen Pharmaceutical: KC1036 combined with PD-1 antibodies and platinum-containing chemotherapy for first-line treatment of advanced recurrent or metastatic esophageal squamous cell carcinoma obtained a clinical trial notification.

Kangchen Pharmaceuticals announced that recently, the company received a clinical trial notification letter for the chemical 1st class innovative drug KC1036, approved and issued by the National Medical Products Administration, regarding the "Clinical Trial for KC1036 Combined with PD-1 Antibody and Platinum-Based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma". The company will conduct the clinical trial in the near future. KC1036 is a chemical 1st class innovative drug independently developed by the company. The indication for the clinical trial is for KC1036 combined with PD-1 antibody and platinum-based chemotherapy as first-line treatment for advanced recurrent or metastatic esophageal squamous cell carcinoma. KC1036 achieves anti-tumor activity through the inhibition of multiple targets such as VEGFR2 and AXL. KC1036 has strong VEGFR vascular targeting abilities, inhibiting tumor cell growth; and by inhibiting AXL, it can improve the host's anti-tumor immune response, thereby avoiding immune escape by the tumor. Currently, clinical studies for KC1036 are being conducted for multiple indications, with over 300 participants enrolled in clinical trials for KC1036.